Form 4: Acrivon CEO & EVP Report Tax Withholding on RSU Vesting

Acrivon Therapeutics' CEO and EVP reported the withholding of shares for tax obligations related to restricted stock unit vesting.

Summary

• Peter Blume-Jensen, President and CEO, and Kristina Masson, EVP Business Operations, reported changes in their beneficial ownership of Acrivon Therapeutics, Inc. common stock.
• On August 21, 2025, 19,905 shares of common stock were withheld by the issuer at a price of $1.32 per share to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
• Following this transaction, Peter Blume-Jensen directly holds 2,126,440 shares.
• Kristina Masson indirectly holds 315,196 shares, which are held by her spouse, Peter Blume-Jensen, with a disclaimer of beneficial ownership except for pecuniary interest.
• Peter Blume-Jensen indirectly holds 315,196 shares, which are held by his spouse, Kristina Masson, with a disclaimer of beneficial ownership except for pecuniary interest.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The filing reports a routine tax withholding event related to the vesting of restricted stock units, which is a standard part of executive compensation and does not indicate a discretionary sale or significant change in company prospects.

Positives

• Routine tax withholding upon RSU vesting indicates the fulfillment of compensation agreements.
• The transaction was executed under a Rule 10b5-1(c) plan, suggesting a pre-planned, non-discretionary event.

Negatives

• A reduction of 19,905 shares from the direct holdings due to tax withholding.

Future Outlook

NA

Industry Context

This transaction reflects a standard practice in executive compensation where restricted stock units (RSUs) vest, and a portion of the shares are automatically withheld by the company to cover the executive's tax liabilities. This is a common mechanism across various industries to manage equity compensation.

Comparison to Industry Standards

• The withholding of shares for tax purposes upon RSU vesting is a widely accepted and common practice for equity compensation in publicly traded companies, aligning with industry standards for executive remuneration and tax compliance.

Corporate Governance

Related Party Transactions

• Disclosure of indirect beneficial ownership between spouses, Peter Blume-Jensen and Kristina Masson, with disclaimers of beneficial ownership except to the extent of pecuniary interest.

Stakeholder Impact

• Shareholders: Provides transparency regarding executive equity holdings and compensation practices.
• Employees: Reflects standard equity compensation practices for executives.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary transaction related to tax withholding upon the vesting of restricted stock units for the CEO and EVP. It does not provide any new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should view this as an administrative disclosure consistent with standard executive compensation practices.

Keywords

Acrivon Therapeutics, ACRV, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Peter Blume-Jensen, Kristina Masson, Beneficial Ownership, Corporate Governance